Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of JNJ-81201887, given as an injection into the eye, for people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This extension study follows participants who took part in earlier parent studies to continue monitoring their health without new treatments given during this phase. The study aims to understand how participants respond over an extended period after the initial treatment. Participants who previously received either a low or high dose of JNJ-81201887, or a sham procedure, in earlier clinical trials will join this long-term extension study. No additional treatments or interventions will be provided during this study. The trial is designed to observe participants without administering further study drugs, focusing on those who were part of the parent studies identified by specific study codes. Throughout the study, participants will be monitored for up to 5 years. Assessments will include checking for any eye-related or systemic side effects, abnormalities in laboratory tests, retinal imaging, and eye examinations. Visual acuity changes will also be measured from baseline up to 42 months. Participants will provide informed consent and be regularly evaluated to track their health and visual function over time.
Actively Recruiting
Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.
Actively Recruiting
Researchers are studying geographic atrophy GA secondary to age-related macular degeneration AMD to understand how different doses of the drug FWY003 affect the condition. This randomized, double-masked, multi-center study aims to characterize the dose-response relationship, as well as assess the efficacy and safety of FWY003 compared to a placebo in adults aged 50 and older with GA due to AMD. Participants are randomly assigned to receive one of three dose levels of FWY003 or a placebo. The study drug or placebo is administered as part of a controlled treatment plan over an 18-month period. The trial includes multiple study groups to compare effects across doses and between the active drug and placebo. During the study, participants will undergo regular assessments including measurements of GA lesion size, visual function tests such as best corrected visual acuity under regular and low luminance, contrast sensitivity, and plasma drug levels. Safety is monitored through adverse event tracking from the first dose through month 19. The main outcome is the change in GA lesion area from baseline to month 18, with treatment effects and safety followed over this period.
Actively Recruiting
Researchers are studying the effectiveness of Faricimab Vabysmo4, an injectable humanized antibody, in treating patients aged 50 and older with subretinal hyperreflective material SHRM associated with type 2 or mixed neovascular membranes in age-related macular degeneration AMD. This phase IV clinical trial aims to determine the percentage of patients who experience resolution of SHRM by week 16. The study is conducted in ophthalmology clinics in Spain and focuses on a rare subtype of macular neovascularization where SHRM is common. Participants will receive Faricimab at a dose of 6 mg0.05 ml via intravitreal injection, following the approved product guidelines. The study involves a single experimental arm where all patients are treated with Faricimab. This drug targets two pathways by neutralizing Ang-2 and VEGF-A and may help stabilize neovascular membranes and reduce SHRM through its dual inhibitory action. During the study, participants will undergo multimodal imaging to assess the resolution of SHRM at week 16. Researchers will monitor visual acuity and retinal health through various assessments to evaluate treatment effects. The total duration includes follow-up to confirm the primary outcome measure. Safety and adherence will be observed throughout, with participants providing informed consent before enrollment.
Actively Recruiting
Researchers are assessing the long-term safety and tolerability of the Port Delivery System with ranibizumab PDS in people with neovascular age-related macular degeneration nAMD who have completed previous related studies or certain visits within those studies. The trial includes two sub-studies to evaluate specific aspects one tests the effectiveness of transscleral photocoagulation to reduce vitreous hemorrhages after PDS implantation, and the other assesses the safety of re-implantation with an updated PDS device. Participants receive the PDS implant with ranibizumab at a concentration of 100 mgmL, administered through refill-exchange procedures at set intervals varying by previous study involvement, typically every 24 weeks with some switching to every 12 weeks later in the trial. The sub-studies involve additional treatments such as laser therapy or re-implantation and follow-up for up to 72 weeks. Treatment schedules and monitoring differ depending on enrollment cohorts and prior participation. Throughout the study, participants undergo regular assessments including eye exams, imaging, and monitoring for adverse events related to the PDS implant and ranibizumab treatment. The study tracks vision changes, ocular health, device safety, and any complications over periods up to 240 weeks or longer if regulatory approval is pending. Participants adherence to visit schedules and safety measures are closely observed as part of the trials long-term evaluation.
Actively Recruiting
Ventilator-Associated Pneumonia VAP is a common bacterial infection in patients who need mechanical ventilation in the Intensive Care Unit ICU. It increases the risk of death, lengthens hospital stays, raises healthcare costs, and leads to more antibiotic use. This research aims to build and maintain a network of ICUs prepared to conduct future clinical trials to evaluate new prevention and treatment options for VAP. The study is a perpetual observational study involving adult ICU patients who are expected to be on mechanical ventilation for more than 48 hours. It gathers data continuously from these patients with consent obtained directly or through authorized representatives or waivers as applicable. The study focuses on identifying patients at risk or diagnosed with VAP and tracks subgroups, including those with confirmed infection causes through laboratory tests. Participants involvement includes monitoring and data collection during their ICU stay with mechanical ventilation. Researchers will measure the number of sites recruiting patients, the number of patients enrolled, and how many studies are conducted through this network over four years. The study also tracks participation in preventive, diagnostic, and treatment studies related to VAP. This ongoing network aims to improve research efficiency and quality in this critical care field.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.